Pakos E E, Stafilas K S, Politis A N, Tsekeris P G, Mitsionis G, Xenakis T A
Department of Orthopaedic Surgery, University Hospital of Ioannina, University of Ioannina, School of Medicine, Ioannina, Greece.
Clin Transl Oncol. 2009 Feb;11(2):103-8. doi: 10.1007/s12094-009-0322-1.
We aimed to evaluate retrospectively the efficacy of combined postoperative radiotherapy and indomethacin compared to indomethacin alone for the prevention of heterotopic ossification (HO) in high-risk patients with congenital disease of hip (CDH) undergoing total hip arthroplasty (THA).
Fifty-five patients received indomethacin alone (Group A), while 44 patients received the combined protocol (Group B). Patients >or=55 years were enrolled in Group B and those younger than 55 years in Group A. Patients were evaluated radiologically for the presence of HO 6 months after the operation.
The incidence of HO in Group A was 34.5% (95% confidence interval 22.2-48.6%), while the respective incidence in Group B patients was 27.3% (95% CI 15.0- 42.8%). The difference was not statistically significant (p=0.5). No significant treatment-related side effects were reported.
This is the first study evaluating the impact of HO prophylaxis in an immiscible population of patients with secondary arthritis due to CDH undergoing THA. Further future randomised evidence is required in order to ascertain the observed trend towards improved efficacy of the combined protocol for HO development.
我们旨在回顾性评估与单独使用消炎痛相比,术后放疗联合消炎痛在预防先天性髋关节疾病(CDH)高危患者行全髋关节置换术(THA)后异位骨化(HO)方面的疗效。
55例患者单独使用消炎痛(A组),44例患者采用联合方案(B组)。年龄≥55岁的患者纳入B组,年龄小于55岁的患者纳入A组。术后6个月对患者进行放射学评估以确定是否存在HO。
A组HO发生率为34.5%(95%置信区间22.2 - 48.6%),而B组患者相应发生率为27.3%(95%CI 15.0 - 42.8%)。差异无统计学意义(p = 0.5)。未报告与治疗相关的显著副作用。
这是第一项评估在因CDH继发关节炎而行THA的不同患者群体中预防HO效果的研究。为确定联合方案在预防HO方面观察到的疗效改善趋势,未来还需要进一步的随机证据。